Novartis announced the failure of two significant Phase 3 drug trials: del-desiran for myotonic dystrophy type 1 and pelacarsen for cardiovascular events. These failures led to a sharp decline in Novartis's stock and negatively impacted its partners, Ionis Pharmaceuticals and Royalty Pharma, due to licensing and royalty agreements tied to the failed drugs.
Novartis experienced a significant stock drop after announcing the failure of two Phase 3 trials: the HARBOR study for del-desiran (myotonic dystrophy type 1) and the Lp(a)HORIZON trial for pelacarsen (cardiovascular events). The del-desiran failure is particularly impactful as it was part of a $12 billion acquisition of Avidity Biosciences' pipeline. The pelacarsen failure directly affected partners Ionis Pharmaceuticals, who licensed the drug to Novartis, and Royalty Pharma, who acquired a royalty interest in pelacarsen. This news represents a major setback for Novartis's pipeline and casts doubt on the value of recent acquisitions, leading to immediate negative short-term implications for all involved stocks. The long-term impact depends on Novartis's ability to pivot and the success of other pipeline assets, but for now, it's a clear hit to investor confidence and future revenue projections for these specific drugs.